SSTR1 is a G protein-coupled receptor for somatostatin, a neuropeptide that functions as a universal endocrine "off-switch" 1. The receptor exhibits higher affinity for somatostatin-14 than somatostatin-28 and is coupled via pertussis toxin-sensitive G proteins to inhibit adenylyl cyclase, while also stimulating phosphotyrosine phosphatase and Na+/H+ exchanger through pertussis toxin-insensitive pathways. SSTR1 mediates critical biological functions including negative regulation of hormone release and cell proliferation 2. In the brain, SSTR1 (referred to as SRIF2 receptor in early studies) modulates neuronal activity through effects on ion conductances and neurotransmitter release, with high expression in the hippocampus, locus coeruleus, and cerebral cortex 3. SSTR1 expression is notably elevated in small cell lung cancer and squamous cell carcinoma compared to adenocarcinoma, making it relevant for potential therapeutic targeting with somatostatin analogues 1. Recent structural studies reveal that SSTR1 accommodates divergent agonists including the FDA-approved panagonist pasireotide through a conserved extended binding pocket, providing framework for developing subtype-selective ligands with improved therapeutic efficacy 2. A candidate pathogenic variant in SSTR1 has been identified in a Saudi Arabian genetic disease cohort, suggesting potential disease association, though confirmation is pending 4.